Pasadena, CA, United States of America

Alyson Weidmann


Average Co-Inventor Count = 3.3

ph-index = 1


Location History:

  • Pasadena, CA (US) (2014 - 2015)
  • San Jose, CA (US) (2018)

Company Filing History:


Years Active: 2014-2018

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Alyson Weidmann: Innovator in Targeted Cancer Therapies

Introduction

Alyson Weidmann is a prominent inventor based in Pasadena, CA (US). She has made significant contributions to the field of cancer research, particularly in the development of targeted therapies for mismatch repair (MMR)-deficient cells. With a total of 3 patents, her work is paving the way for more effective cancer treatments.

Latest Patents

Alyson's latest patents include innovative compositions that utilize metalloinsertor conjugates. One of her notable inventions is a composition that specifically targets MMR-deficient cells, which includes a complex represented by Formula I. This selective cytotoxicity may be induced in MMR-deficient cells upon uptake of the metalloinsertor conjugate. Additionally, she has developed metalloinsertor complexes conjugated with platinum (Pt), allowing for more specific targeting of platinum anticancer agents. Another significant patent involves metalloinsertor complexes targeted to DNA mismatches, which also induce selective cytotoxicity in MMR-deficient cells.

Career Highlights

Alyson Weidmann is affiliated with the California Institute of Technology, where she continues her research and development in the field of cancer therapies. Her innovative approaches and dedication to science have positioned her as a leading figure in her area of expertise.

Collaborations

Alyson has collaborated with esteemed colleagues such as Jacqueline K. Barton and Alexis Christine Komor. These partnerships have further enhanced her research and contributed to the advancement of targeted cancer therapies.

Conclusion

Alyson Weidmann's work in developing targeted therapies for cancer represents a significant advancement in medical science. Her innovative patents and collaborations highlight her commitment to improving treatment options for patients with MMR-deficient cancers.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…